TEVA logo

TEVA Cash And Cash Equivalents

Annual Cash & Cash Equivalents

$3.30 B
+$74.00 M+2.29%

December 31, 2024


Summary


Performance

TEVA Cash And Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherTEVAbalance sheetmetrics:

Quarterly Cash And Cash Equivalents

$3.30 B
-$19.00 M-0.57%

December 31, 2024


Summary


Performance

TEVA Quarterly Cash And Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherTEVAbalance sheetmetrics:

Cash And Cash Equivalents Formula

Cash & Cash Equivalents = Cash + Short-Term Investments

TEVA Cash And Cash Equivalents Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+2.3%+10.3%
3 y3 years+52.4%+60.4%
5 y5 years+67.1%+51.6%

TEVA Cash And Cash Equivalents Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+52.4%-0.6%+60.4%
5 y5-yearat high+67.1%-0.6%+89.3%
alltimeall time-52.5%>+9999.0%-52.8%>+9999.0%

Teva Pharmaceutical Industries Limited Cash And Cash Equivalents History

DateAnnualQuarterly
Dec 2024
$3.30 B(+2.3%)
$3.30 B(-0.6%)
Sep 2024
-
$3.32 B(+47.0%)
Jun 2024
-
$2.26 B(-24.5%)
Mar 2024
-
$2.99 B(-7.3%)
Dec 2023
$3.23 B(+15.2%)
$3.23 B(+43.4%)
Sep 2023
-
$2.25 B(-15.7%)
Jun 2023
-
$2.67 B(+24.5%)
Mar 2023
-
$2.14 B(-23.5%)
Dec 2022
$2.80 B(+29.4%)
$2.80 B(+25.9%)
Sep 2022
-
$2.23 B(+8.1%)
Jun 2022
-
$2.06 B(-5.4%)
Mar 2022
-
$2.17 B(+0.5%)
Dec 2021
$2.17 B(-0.6%)
$2.17 B(+5.9%)
Sep 2021
-
$2.04 B(-16.1%)
Jun 2021
-
$2.44 B(+39.8%)
Mar 2021
-
$1.74 B(-19.9%)
Dec 2020
$2.18 B(+10.2%)
$2.18 B(+19.2%)
Sep 2020
-
$1.83 B(-23.9%)
Jun 2020
-
$2.40 B(+33.1%)
Mar 2020
-
$1.80 B(-8.7%)
Dec 2019
$1.98 B(+10.8%)
$1.98 B(+59.1%)
Sep 2019
-
$1.24 B(-42.7%)
Jun 2019
-
$2.17 B(+9.7%)
Mar 2019
-
$1.97 B(+10.7%)
Dec 2018
$1.78 B(+85.0%)
$1.78 B(-5.0%)
Sep 2018
-
$1.88 B(+0.8%)
Jun 2018
-
$1.86 B(+31.2%)
Mar 2018
-
$1.42 B(+47.2%)
Dec 2017
$963.00 M(-2.5%)
$963.00 M(+41.6%)
Sep 2017
-
$680.00 M(+13.5%)
Jun 2017
-
$599.00 M(-33.4%)
Mar 2017
-
$900.00 M(-8.9%)
Dec 2016
$988.00 M(-85.8%)
$988.00 M(-36.5%)
Sep 2016
-
$1.56 B(-77.7%)
Jun 2016
-
$6.98 B(+17.1%)
Mar 2016
-
$5.96 B(-14.1%)
Dec 2015
$6.95 B(+212.0%)
$6.95 B(+648.5%)
Sep 2015
-
$928.00 M(-13.1%)
Jun 2015
-
$1.07 B(-68.6%)
Mar 2015
-
$3.40 B(+52.6%)
Dec 2014
$2.23 B(+114.5%)
$2.23 B(+51.1%)
Sep 2014
-
$1.47 B(+55.2%)
Jun 2014
-
$949.00 M(+5.3%)
Mar 2014
-
$901.00 M(-13.2%)
Dec 2013
$1.04 B(-63.9%)
$1.04 B(-9.6%)
Sep 2013
-
$1.15 B(-7.8%)
Jun 2013
-
$1.25 B(-10.7%)
Mar 2013
-
$1.39 B(-51.6%)
Dec 2012
$2.88 B(+162.7%)
$2.88 B(+101.0%)
Sep 2012
-
$1.43 B(+20.5%)
Jun 2012
-
$1.19 B(+11.9%)
Mar 2012
-
$1.06 B(-3.1%)
Dec 2011
$1.10 B(-12.2%)
$1.10 B(+1.0%)
Sep 2011
-
$1.08 B(-4.7%)
Jun 2011
-
$1.14 B(+58.0%)
Mar 2011
-
$721.00 M(-42.2%)
Dec 2010
$1.25 B
$1.25 B(+33.5%)
Sep 2010
-
$935.00 M(-80.7%)
Jun 2010
-
$4.85 B(+106.0%)
DateAnnualQuarterly
Mar 2010
-
$2.36 B(+18.1%)
Dec 2009
$2.00 B(+7.6%)
$2.00 B(+24.8%)
Sep 2009
-
$1.60 B(-9.3%)
Jun 2009
-
$1.76 B(-25.1%)
Mar 2009
-
$2.35 B(+26.8%)
Dec 2008
$1.85 B(+24.6%)
$1.85 B(-35.0%)
Sep 2008
-
$2.85 B(+14.9%)
Jun 2008
-
$2.48 B(-1.0%)
Mar 2008
-
$2.51 B(+68.6%)
Dec 2007
$1.49 B(+11.7%)
$1.49 B(-1.3%)
Sep 2007
-
$1.51 B(-6.8%)
Jun 2007
-
$1.62 B(+37.6%)
Mar 2007
-
$1.18 B(-11.7%)
Dec 2006
$1.33 B(+4.4%)
$1.33 B(+59.8%)
Sep 2006
-
$833.50 M(-3.4%)
Jun 2006
-
$863.10 M(-10.9%)
Mar 2006
-
$968.30 M(-24.1%)
Dec 2005
$1.28 B(+62.8%)
$1.28 B(+81.5%)
Sep 2005
-
$703.10 M(-15.7%)
Jun 2005
-
$834.30 M(+18.9%)
Mar 2005
-
$701.60 M(-10.5%)
Dec 2004
$784.00 M(-25.8%)
$784.00 M(-14.6%)
Sep 2004
-
$918.10 M(+29.0%)
Jun 2004
-
$711.70 M(+0.2%)
Mar 2004
-
$710.00 M(-32.8%)
Dec 2003
$1.06 B(+30.5%)
$1.06 B(+32.1%)
Sep 2003
-
$800.10 M(-9.0%)
Jun 2003
-
$879.30 M(-5.4%)
Mar 2003
-
$929.40 M(+14.8%)
Dec 2002
$809.90 M(+5.3%)
$809.90 M(+117.8%)
Sep 2002
-
$371.80 M(-35.5%)
Jun 2002
-
$576.30 M(-11.9%)
Mar 2002
-
$653.80 M(-15.0%)
Dec 2001
$768.92 M(+82.8%)
$768.92 M(-4.3%)
Sep 2001
-
$803.30 M(+139.0%)
Jun 2001
-
$336.09 M(-4.8%)
Mar 2001
-
$353.06 M(-16.1%)
Dec 2000
$420.63 M(+445.0%)
$420.63 M(+350.3%)
Jun 2000
-
$93.41 M(-13.7%)
Mar 2000
-
$108.25 M(+40.3%)
Dec 1999
$77.18 M(+63.9%)
$77.18 M(-35.9%)
Sep 1999
-
$120.40 M(+115.4%)
Jun 1999
-
$55.90 M(-19.9%)
Mar 1999
-
$69.80 M(+48.2%)
Dec 1998
$47.10 M(-7.5%)
$47.10 M(-15.6%)
Sep 1998
-
$55.80 M(-41.4%)
Jun 1998
-
$95.30 M(+56.5%)
Mar 1998
-
$60.90 M(+19.6%)
Dec 1997
$50.90 M(-16.8%)
$50.90 M(-16.8%)
Dec 1996
$61.20 M(-5.7%)
$61.20 M(-5.7%)
Dec 1995
$64.90 M(+53.1%)
$64.90 M(+53.1%)
Dec 1994
$42.40 M(+6.3%)
$42.40 M(+6.3%)
Dec 1993
$39.90 M(+189.1%)
$39.90 M(+189.1%)
Dec 1992
$13.80 M(+74.7%)
$13.80 M(+74.7%)
Dec 1991
$7.90 M(-48.7%)
$7.90 M(-48.7%)
Dec 1990
$15.40 M(+234.8%)
$15.40 M(+234.8%)
Dec 1989
$4.60 M(-64.9%)
$4.60 M(-64.9%)
Dec 1988
$13.10 M(-17.6%)
$13.10 M(-17.6%)
Mar 1987
$15.90 M(-29.0%)
$15.90 M(-29.0%)
Mar 1986
$22.40 M
$22.40 M

FAQ

  • What is Teva Pharmaceutical Industries Limited annual cash & cash equivalents?
  • What is the all time high annual cash & cash equivalents for Teva Pharmaceutical Industries Limited?
  • What is Teva Pharmaceutical Industries Limited annual cash & cash equivalents year-on-year change?
  • What is Teva Pharmaceutical Industries Limited quarterly cash and cash equivalents?
  • What is the all time high quarterly cash and cash equivalents for Teva Pharmaceutical Industries Limited?
  • What is Teva Pharmaceutical Industries Limited quarterly cash and cash equivalents year-on-year change?

What is Teva Pharmaceutical Industries Limited annual cash & cash equivalents?

The current annual cash & cash equivalents of TEVA is $3.30 B

What is the all time high annual cash & cash equivalents for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited all-time high annual cash & cash equivalents is $6.95 B

What is Teva Pharmaceutical Industries Limited annual cash & cash equivalents year-on-year change?

Over the past year, TEVA annual cash & cash equivalents has changed by +$74.00 M (+2.29%)

What is Teva Pharmaceutical Industries Limited quarterly cash and cash equivalents?

The current quarterly cash and cash equivalents of TEVA is $3.30 B

What is the all time high quarterly cash and cash equivalents for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited all-time high quarterly cash and cash equivalents is $6.98 B

What is Teva Pharmaceutical Industries Limited quarterly cash and cash equivalents year-on-year change?

Over the past year, TEVA quarterly cash and cash equivalents has changed by +$309.00 M (+10.33%)